About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical leader that discovers, develops, and delivers life-changing medicines to people around the world. Founded in 1876, Lilly is known for breakthrough treatments in diabetes, oncology, immunology, and neuroscience.
Our Heritage
Founded by Colonel Eli Lilly in 1876 in Indianapolis, the company pioneered many pharmaceutical innovations including mass-produced insulin in the 1920s. Today, Lilly is at the forefront of GLP-1 receptor agonists for diabetes and weight management.
Key Therapeutic Areas
Lilly is a world leader in diabetes care with drugs like Mounjaro (tirzepatide) and Trulicity. In oncology, Lilly offers Verzenio, Cyramza, and Retevmo. The company also has a strong portfolio in immunology (Taltz, Olumiant) and neuroscience.
Innovation Pipeline
Lilly invests heavily in research, with a pipeline spanning Alzheimer's disease, gene therapies, and next-generation diabetes treatments. The company's donanemab (Kisunla) received FDA approval for early Alzheimer's disease in 2024.
Financial Performance
Lilly reported $34.1 billion in revenue in 2023, driven largely by the phenomenal success of Mounjaro and its weight-loss counterpart Zepbound. The company is one of the most valuable pharmaceutical companies globally.
Leadership
David A. Ricks serves as Chairman and CEO, leading the company since 2017. Under his leadership, Lilly has achieved unprecedented growth driven by its diabetes and obesity franchise.